Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Eutelsat Shares Face Intense Selling Pressure

Robert Sasse by Robert Sasse
December 21, 2025
in Analysis, European Markets, Space, Telecommunications
0
Eutelsat Stock
0
SHARES
21
VIEWS
Share on FacebookShare on Twitter

Eutelsat shares concluded a punishing week by falling to fresh lows on Friday, closing at €1.61. This represented a weekly decline of 23%, with the session itself seeing a 5% drop. The severe downturn persists despite significant corporate announcements, overshadowed entirely by the dilutive impact of a recent capital increase.

Capital Raise Casts a Long Shadow

The primary driver of the sell-off remains the recently completed €1.5 billion financing round. Nearly 500 million new shares were issued at a subscription price of €1.35. This discounted price level continues to act as a powerful anchor, stifling any potential for a sustained share price recovery and creating persistent overhang in the market.

Next-Generation Satellite Plans Fail to Impress

In a strategic update on Thursday, Eutelsat OneWeb outlined the roadmap for its second-generation satellite constellation. The plan involves launching 340 Gen-2 satellites by 2027, with a focus on bolstering services for enterprise and government clients. The company has again selected the Indian Space Research Organisation (ISRO) and SpaceX as launch partners.

However, this news failed to generate any positive momentum within the investment community. Market attention remains fixed on the company’s existing financial structure rather than its future operational strategy.

Analyst Outlook and Shareholder Sentiment

Analyst commentary has provided little support. BNP Paribas recently issued a “Market Performance” rating for the stock, accompanied by a price target of €2.00. While this suggests a theoretical upside of 24%, the analysts concurrently highlighted ongoing operational risks, tempering the bullish implication of the target.

Should investors sell immediately? Or is it worth buying Eutelsat?

Sentiment was further damaged in early December by the actions of a major shareholder. SoftBank’s exit, including the sale of subscription rights for approximately 26 million shares, signaled clear skepticism from a key longstanding investor.

Technical and Fundamental Crossroads

From a technical perspective, the stock is deeply oversold, with its Relative Strength Index (RSI) hovering around 22. The immediate focus is whether the €1.50 to €1.60 support zone will hold. A breach of this level in the coming holiday-shortened week could see the share price test the capital increase floor of €1.35.

Fundamentally, the path to regaining investor confidence appears narrow. Eutelsat must announce substantial, concrete contracts for its Gen-2 constellation in a timely manner. Only demonstrable commercial success can potentially outweigh the market’s acute concerns over shareholder dilution. The company also continues to face the formidable sector-wide challenge posed by competitors like Starlink, which already operates thousands of active satellites.

Key Data Points:
* Friday’s Closing Price: €1.61 (-5% for the session)
* Weekly Performance: -23%
* Capital Increase Subscription Price: €1.35
* BNP Paribas Price Target: €2.00

Ad

Eutelsat Stock: Buy or Sell?! New Eutelsat Analysis from February 8 delivers the answer:

The latest Eutelsat figures speak for themselves: Urgent action needed for Eutelsat investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Eutelsat: Buy or sell? Read more here...

Tags: Eutelsat
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Next Post
SmartRent Stock

SmartRent Leadership Demonstrates Confidence with Significant Share Purchase

Lexicon Stock

Lexicon Pharmaceuticals Approaches Critical Development Milestones

Solana Stock

Solana's Fundamental Milestone: Outearning Ethereum Amid Market Turbulence

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com